Description: CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The company has a collaboration agreement with Danish company Zyneyro to develop a treatment for chronic pain conditions. CombiGene AB (publ) was incorporated in 1990 and is based in Lidingö, Sweden.
Home Page: www.combigene.com
Agavagen 52A
Lidingö,
181 55
Sweden
Phone:
46 8 35 73 55
Officers
| Name | Title |
|---|---|
| Mr. Peter Ekolind | Chief Executive Officer |
| Associate Prof. David Woldbye | Scientific Founder |
| Prof. Merab Kokaia Ph.D. | Scientific Founder |
| Ms. Louise Aspenberg | Chief Financial Officer |
| Ms. Annika Ericson | Chief Scientific Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.426 |
| Price-to-Sales TTM: | 0.971 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |